# An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/an-her3-targeting-antibody-drug-conjugate-incorporating-a-dna-topoisomerase-i/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kimio Yonesaka,Naoki Takegawa,Satomi Watanabe,Koji Haratani,Hisato Kawakami,Kazuko Sakai,Yasutaka Chiba,Naoyuki Maeda,Takashi Kagari,Kenji Hirotani,Kazuto Nishio,Kazuhiko Nakagawa |
| Citations | 102 |
| DOI | 10.1038/s41388-018-0517-4 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2896311970 |
| PMID | 30302022 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Satomi Watanabe](https://scholariq.org/researchers/satomi-watanabe/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.